Lanreotide reduces hospital costs for metastatic GEP-NETs

Utilisation of lanreotide appears to reduce hospital costs compared with octreotide in US patients with metastatic gastroenteropancreatic neuroendocrine tumours (mGEP-NETs), according to findings of a Ipsen Biopharmaceuticals-funded study published in *ClinicoEconomics and Outcomes Research*.

Budget impact modelling was used to evaluate hospital costs in a hypothetical cohort of 500 patients with mGEP-NETs treated with somatostatins, including lanreotide (Somatuline Depot) and octreotide (Sandostatin LAR*, from a US hospital perspective. Costs included drug acquisition, preparation and administration costs. It was assumed that 78% of patients (n=313) were eligible for somatostatins and the time per injection was 66 sec with lanreotide and 329 sec with octreotide. In scenario one, lanreotide and octreotide were utilised in 5% and 95% of patients, respectively, and in scenario two, the drugs were utilised in 30% and 70%, respectively.

The estimated total hospital cost per patient was \$83 473** with lanreotide and \$89 673 with octreotide.

When lanreotide was utilised in 5% of patients, projected annual hospital costs for the 500 patient population were \$27 970 455. Projected annual hospital costs decreased by \$488 615 when lanreotide utilisation was increased from 5% to 30%.

One-way sensitivity analyses showed the results were sensitive to dosing assumptions as well as drug acquisition costs.

"The finding that increased utilization of lanreotide can reduce costs could be beneficial to payers, hospital systems, clinicians, and others concerned about the cost of care for mGEP-NET patients," commented the authors.

* long-acting release

** 2017 US dollars

Ortendahl JD, et al. Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. ClinicoEconomics and Outcomes Research 2017: 495-503, No. 9, 16 Aug 2017. Available from: URL: https://doi.org/10.2147/CEOR.S140866 803265932